RU2404793C1 - Стимулятор половой, сексуальной и репродуктивной функции - Google Patents
Стимулятор половой, сексуальной и репродуктивной функции Download PDFInfo
- Publication number
- RU2404793C1 RU2404793C1 RU2009121281/15A RU2009121281A RU2404793C1 RU 2404793 C1 RU2404793 C1 RU 2404793C1 RU 2009121281/15 A RU2009121281/15 A RU 2009121281/15A RU 2009121281 A RU2009121281 A RU 2009121281A RU 2404793 C1 RU2404793 C1 RU 2404793C1
- Authority
- RU
- Russia
- Prior art keywords
- sexual
- points
- pro
- patients
- intercourse
- Prior art date
Links
- 230000001568 sexual effect Effects 0.000 title claims abstract description 113
- 230000001850 reproductive effect Effects 0.000 title claims abstract description 24
- 210000004392 genitalia Anatomy 0.000 title abstract description 5
- 108010046399 TP 7 Proteins 0.000 claims abstract description 33
- JTDTXGMXNXBGBZ-YVHUGQOKSA-N (2s)-1-[2-[[(2s)-1-[(2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@H](C(=O)NCC(=O)N2[C@@H](CCC2)C(O)=O)CCC1 JTDTXGMXNXBGBZ-YVHUGQOKSA-N 0.000 claims abstract description 32
- 241000124008 Mammalia Species 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 abstract description 43
- 239000003814 drug Substances 0.000 abstract description 25
- 230000006870 function Effects 0.000 abstract description 18
- 230000004936 stimulating effect Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract 1
- 230000036299 sexual function Effects 0.000 description 47
- 238000011282 treatment Methods 0.000 description 46
- 241000700159 Rattus Species 0.000 description 24
- 229940079593 drug Drugs 0.000 description 19
- 230000001965 increasing effect Effects 0.000 description 19
- 238000005461 lubrication Methods 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 230000036642 wellbeing Effects 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 230000035935 pregnancy Effects 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 230000003442 weekly effect Effects 0.000 description 12
- 206010021703 Indifference Diseases 0.000 description 11
- 201000001880 Sexual dysfunction Diseases 0.000 description 11
- 231100000872 sexual dysfunction Toxicity 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 230000037007 arousal Effects 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 9
- 230000007170 pathology Effects 0.000 description 9
- 206010063659 Aversion Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000004064 dysfunction Effects 0.000 description 8
- 238000011002 quantification Methods 0.000 description 8
- 230000002708 enhancing effect Effects 0.000 description 7
- 230000036512 infertility Effects 0.000 description 6
- 208000000509 infertility Diseases 0.000 description 6
- 231100000535 infertility Toxicity 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 230000003054 hormonal effect Effects 0.000 description 4
- 230000013011 mating Effects 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 230000010539 reproductive behavior Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000035606 childbirth Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000003370 grooming effect Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 102400000050 Oxytocin Human genes 0.000 description 2
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 2
- 101800000989 Oxytocin Proteins 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 206010047924 Wheezing Diseases 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000000049 anti-anxiety effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 229940015047 chorionic gonadotropin Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- 231100000544 menstrual irregularity Toxicity 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 2
- 229960001723 oxytocin Drugs 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000035946 sexual desire Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- 208000005641 Adenomyosis Diseases 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010066364 Hypersexuality Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010024870 Loss of libido Diseases 0.000 description 1
- 206010027295 Menometrorrhagia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000035175 Oligomenorrhea Diseases 0.000 description 1
- 206010030295 Oligomenorrhoea Diseases 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 1
- 102400001107 Secretory component Human genes 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 235000006545 Ziziphus mauritiana Nutrition 0.000 description 1
- 240000000038 Ziziphus mauritiana Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000003975 dentin desensitizing agent Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 201000009274 endometriosis of uterus Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 238000009957 hemming Methods 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000009486 mnemonic function Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- XNOPRXBHLZRZKH-MQYCRUOZSA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1C(CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-MQYCRUOZSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229940033942 zoladex Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2009121281/15A RU2404793C1 (ru) | 2009-06-04 | 2009-06-04 | Стимулятор половой, сексуальной и репродуктивной функции |
| CN201080033918.6A CN102481335B (zh) | 2009-06-04 | 2010-06-01 | 生殖器功能、性功能和生殖功能的刺激物 |
| CA2764351A CA2764351C (en) | 2009-06-04 | 2010-06-01 | Stimulator of genital, sexual and reproductive function |
| JP2012513900A JP5643816B2 (ja) | 2009-06-04 | 2010-06-01 | 生殖、性的、および繁殖機能の刺激剤 |
| ES10783644T ES2831673T3 (es) | 2009-06-04 | 2010-06-01 | Estimulador de la función genital, sexual y reproductiva |
| PCT/RU2010/000285 WO2010140926A1 (ru) | 2009-06-04 | 2010-06-01 | Стимулятор половой, сексуальной и репродуктивной функции |
| US13/376,023 US8883741B2 (en) | 2009-06-04 | 2010-06-01 | Stimulator of genital, sexual and reproductive function |
| BRPI1011071A BRPI1011071B8 (pt) | 2009-06-04 | 2010-06-01 | uso de um heptapeptídeo para estimular a função genital, sexual ou reprodutiva em um mamífero |
| EP10783644.7A EP2465521B1 (en) | 2009-06-04 | 2010-06-01 | Stimulator of genital, sexual and reproductive function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2009121281/15A RU2404793C1 (ru) | 2009-06-04 | 2009-06-04 | Стимулятор половой, сексуальной и репродуктивной функции |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2404793C1 true RU2404793C1 (ru) | 2010-11-27 |
Family
ID=43297916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009121281/15A RU2404793C1 (ru) | 2009-06-04 | 2009-06-04 | Стимулятор половой, сексуальной и репродуктивной функции |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8883741B2 (enExample) |
| EP (1) | EP2465521B1 (enExample) |
| JP (1) | JP5643816B2 (enExample) |
| CN (1) | CN102481335B (enExample) |
| BR (1) | BRPI1011071B8 (enExample) |
| CA (1) | CA2764351C (enExample) |
| ES (1) | ES2831673T3 (enExample) |
| RU (1) | RU2404793C1 (enExample) |
| WO (1) | WO2010140926A1 (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013151467A3 (ru) * | 2012-03-28 | 2014-01-09 | Общество С Ограниченной Ответственностью "Айвикс" | Способ получения рекомбинантного пептида и полученный пептид |
| US8883741B2 (en) | 2009-06-04 | 2014-11-11 | Bio Peptid Company Limited | Stimulator of genital, sexual and reproductive function |
| WO2018080353A1 (ru) * | 2016-10-24 | 2018-05-03 | Общество С Ограниченной Ответственностью "Айвикс" | Фармацевтическая композиция и способ лечения женских сексуальных дисфункций |
| US10836794B2 (en) | 2016-10-24 | 2020-11-17 | “Ivix” Ltd. | Group of peptides for treating female sexual dysfunction |
| RU2837354C1 (ru) * | 2024-07-13 | 2025-03-31 | Общество С Ограниченной Ответственностью Пептидпро | Фармацевтическая композиция для лечения или профилактики нарушений эректильной функции у мужчин и ее применение |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113413456A (zh) * | 2013-05-28 | 2021-09-21 | Ovb(爱尔兰)有限公司 | 用于生产重组肽的方法及所得到的肽 |
| US9717903B1 (en) | 2015-03-17 | 2017-08-01 | Gary Barrett | Electronic process to restore, improve and/or strengthen the libido; method to mend the sex drive in males and females |
| JP2018118973A (ja) * | 2018-02-23 | 2018-08-02 | アイビックス・リミテッドＩｖｉｘ Ｌｔｄ． | 組換えペプチドを生産するための方法および得られるペプチド |
| JP6858227B2 (ja) * | 2019-07-11 | 2021-04-14 | アイビックス・リミテッドＩｖｉｘ Ｌｔｄ． | 組換えペプチドを生産するための方法および得られるペプチド |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU1124544C (ru) * | 1983-06-30 | 1995-01-09 | Институт молекулярной генетики РАН | Гептапептид, обладающий свойствами психостимулятора пролонгированного действия с иммунотропной активность |
| RU2252779C1 (ru) * | 2003-09-23 | 2005-05-27 | Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) | Способ профилактики и лечения язв желудочно-кишечного тракта |
| RU2317099C1 (ru) * | 2006-08-29 | 2008-02-20 | Открытое Акционерное Общество Завод Экологической Техники И Экопитания "Диод" | Лечебно-профилактическое средство для восстановления нарушений половых функций, способ получения масла зародышей пшеницы и способ получения концентрата масла зародышей пшеницы для восстановления нарушений половых функций |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2058791C1 (ru) | 1989-01-11 | 1996-04-27 | Государственное предприятие "Элер-микро" | Стимулятор репродуктивной способности у теплокровных животных |
| US5872100A (en) | 1990-05-11 | 1999-02-16 | Deghenghi; Romano | Peptides containing D-2-Alkyl-Tryptophan |
| JP3204510B2 (ja) | 1993-04-05 | 2001-09-04 | コンペティティブ テクノロジーズ，インク． | 勃起不全の診断および治療 |
| US5932548A (en) | 1998-06-03 | 1999-08-03 | Deghenghi; Romano | Lysine containing peptides for treatment of heart disease |
| RU2155065C1 (ru) | 1999-04-23 | 2000-08-27 | Институт молекулярной генетики РАН | Анксиолитическое средство и фармацевтическая композиция анксиолитического действия |
| US6211156B1 (en) | 1999-11-10 | 2001-04-03 | Asta Medica A.G. | Peptides for treatment of erectile dysfunction |
| RU2290195C1 (ru) * | 2005-04-21 | 2006-12-27 | Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) | Средство с антикоагулянтной, антитромбоцитарной, антитромботической, фибриндеполимеризационной и фибринолитической активностями |
| CN101302246B (zh) * | 2007-05-09 | 2011-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 黑色素皮质激素受体七肽类激动剂及其制备方法和用途 |
| RU2404793C1 (ru) | 2009-06-04 | 2010-11-27 | Общество с ограниченной ответственностью Био Пептид | Стимулятор половой, сексуальной и репродуктивной функции |
| EA013948B1 (ru) | 2009-06-08 | 2010-08-30 | Общество С Ограниченной Ответственностью "Витанта" | Средство, активирующее половую функцию |
-
2009
- 2009-06-04 RU RU2009121281/15A patent/RU2404793C1/ru active IP Right Revival
-
2010
- 2010-06-01 CN CN201080033918.6A patent/CN102481335B/zh active Active
- 2010-06-01 CA CA2764351A patent/CA2764351C/en active Active
- 2010-06-01 EP EP10783644.7A patent/EP2465521B1/en active Active
- 2010-06-01 BR BRPI1011071A patent/BRPI1011071B8/pt active IP Right Grant
- 2010-06-01 ES ES10783644T patent/ES2831673T3/es active Active
- 2010-06-01 JP JP2012513900A patent/JP5643816B2/ja active Active
- 2010-06-01 WO PCT/RU2010/000285 patent/WO2010140926A1/ru not_active Ceased
- 2010-06-01 US US13/376,023 patent/US8883741B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU1124544C (ru) * | 1983-06-30 | 1995-01-09 | Институт молекулярной генетики РАН | Гептапептид, обладающий свойствами психостимулятора пролонгированного действия с иммунотропной активность |
| RU2252779C1 (ru) * | 2003-09-23 | 2005-05-27 | Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) | Способ профилактики и лечения язв желудочно-кишечного тракта |
| RU2317099C1 (ru) * | 2006-08-29 | 2008-02-20 | Открытое Акционерное Общество Завод Экологической Техники И Экопитания "Диод" | Лечебно-профилактическое средство для восстановления нарушений половых функций, способ получения масла зародышей пшеницы и способ получения концентрата масла зародышей пшеницы для восстановления нарушений половых функций |
Non-Patent Citations (1)
| Title |
|---|
| Semenova TP, Kozlovskaya MM, Zuikov AV, Kozlovskii II, Zakharova NM, Andreeva LA. «Use of Selank to correct measures of integrative brain activity and biogenic amine levels in adult rats resulting from antenatal hypoxia.», Neurosci Behav Physiol. 2008 Feb; 38(2):203-7. * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8883741B2 (en) | 2009-06-04 | 2014-11-11 | Bio Peptid Company Limited | Stimulator of genital, sexual and reproductive function |
| WO2013151467A3 (ru) * | 2012-03-28 | 2014-01-09 | Общество С Ограниченной Ответственностью "Айвикс" | Способ получения рекомбинантного пептида и полученный пептид |
| RU2507212C2 (ru) * | 2012-03-28 | 2014-02-20 | Общество С Ограниченной Ответственностью "Айвикс" | Способ получения рекомбинантного пептида и полученный пептид |
| US9409947B2 (en) | 2012-03-28 | 2016-08-09 | “Ivix” Ltd. | Method for producing a recombinant peptide and resultant peptide |
| WO2018080353A1 (ru) * | 2016-10-24 | 2018-05-03 | Общество С Ограниченной Ответственностью "Айвикс" | Фармацевтическая композиция и способ лечения женских сексуальных дисфункций |
| RU2655763C2 (ru) * | 2016-10-24 | 2018-05-29 | Общество С Ограниченной Ответственностью "Айвикс" | Фармацевтическая композиция и способ лечения женских сексуальных дисфункций |
| US10836794B2 (en) | 2016-10-24 | 2020-11-17 | “Ivix” Ltd. | Group of peptides for treating female sexual dysfunction |
| RU2837354C1 (ru) * | 2024-07-13 | 2025-03-31 | Общество С Ограниченной Ответственностью Пептидпро | Фармацевтическая композиция для лечения или профилактики нарушений эректильной функции у мужчин и ее применение |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2764351A1 (en) | 2010-12-09 |
| CN102481335A (zh) | 2012-05-30 |
| BRPI1011071B1 (pt) | 2020-10-20 |
| ES2831673T3 (es) | 2021-06-09 |
| US8883741B2 (en) | 2014-11-11 |
| EP2465521A1 (en) | 2012-06-20 |
| CA2764351C (en) | 2016-08-16 |
| BRPI1011071A2 (pt) | 2016-09-27 |
| EP2465521B1 (en) | 2020-10-14 |
| US20120129791A1 (en) | 2012-05-24 |
| CN102481335B (zh) | 2014-02-26 |
| JP5643816B2 (ja) | 2014-12-17 |
| JP2012528856A (ja) | 2012-11-15 |
| WO2010140926A1 (ru) | 2010-12-09 |
| BRPI1011071B8 (pt) | 2021-05-25 |
| EP2465521A4 (en) | 2012-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2404793C1 (ru) | Стимулятор половой, сексуальной и репродуктивной функции | |
| Barrier et al. | Efficacy of anti-tumor necrosis factor therapy in the treatment of spontaneous endometriosis in baboons | |
| Letaif et al. | Effects of estrogen on functional and neurological recovery after spinal cord injury: An experimental study with rats | |
| Welsh et al. | Management of common vulval conditions | |
| Gazaway et al. | Prevention of preterm labor and premature rupture of the membranes | |
| Kelley | Sterility in the Female with Special Reference to Psychic Factors: Part I: A Review of the Literature | |
| Moghani et al. | Investigating the effect of edible pineapple on the ripening of the cervix and the onset of labor. | |
| RU2784947C1 (ru) | Способ лечения наружного генитального эндометриоза с выраженным болевым синдромом | |
| Akkoca et al. | The prevalence of urinary incontinence, sexual dysfunction and quality of life in women of reproductive age admitted to urogynecology departments | |
| Prilepskaya et al. | Clinical study (phase II) of the efficacy and safety of Longidase (suppositories) in patients with adhesions due to pelvic inflammatory disease: A blinded, placebo-controlled, randomized study | |
| Sharipovich | IN CHOLEDOCHOLITIASIS CHOLEDOXOSCOPY SPECIFIC FEATURES AND PROBLEMS | |
| Rehman et al. | Ovulation induction in clomiphene citrate resistant patient by human menopausal gonadotrophin | |
| Goold et al. | The patient with psychosexual problems | |
| Griffiths et al. | Sexual dysfunction in intensive care survivors | |
| RU2480225C1 (ru) | Способ лечения воспалительных заболеваний половой сферы у женщин | |
| Diaconu et al. | ANALYSIS OF POSSIBLE POSITIVE EFFECTS OF OXYTOCIN ADMINISTERED DURING BIRTH ON THE NEUROMOTOR DEVELOPMENT OF THE 0-5 YEAR-OLD-CHILDREN. | |
| Danappagoudar et al. | Effective Ayurvedic management of Infertility due to low AMH in Elderly Women-Case Study | |
| RU2440817C1 (ru) | Средство для лечения бактериального вагиноза | |
| VaGInal rInG | CONTRACEPTIVE VAGINAL RING EDUCATION HANDOUT | |
| Jacobs | The treatment of homosexuality | |
| McCullough | Ejaculatory disorders | |
| Zieliński et al. | ANAPHYLAXIS AND ANAPHYLACTIC SHOCK | |
| Fry et al. | The Family Good Health Guide: Common Sense on Common Health Problems | |
| Rebal Jr et al. | Unusual sexual syndromes | |
| Orr et al. | Tag Archives: Cancers in Women |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| QB4A | Licence on use of patent |
Free format text: LICENCE Effective date: 20131111 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20140605 |
|
| NF4A | Reinstatement of patent |
Effective date: 20150627 |
|
| QZ41 | Official registration of changes to a registered agreement (patent) |
Free format text: LICENCE FORMERLY AGREED ON 20131111 Effective date: 20150629 |
|
| QZ41 | Official registration of changes to a registered agreement (patent) |
Free format text: LICENCE FORMERLY AGREED ON 20131111 Effective date: 20150723 |
|
| PD4A | Correction of name of patent owner | ||
| QC41 | Official registration of the termination of the licence agreement or other agreements on the disposal of an exclusive right |
Free format text: LICENCE FORMERLY AGREED ON 20131111 Effective date: 20200408 |
|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20200807 |
|
| PD4A | Correction of name of patent owner |